S

Sanofi

Global pharma company; vaccines and R&D

Personnel Cost Controlling Manager

Full-TimeDeadline 12/30/26
HUF15.8M - HUF21.1M
Senior
Bachelor's, MBA
Budapest, Hungary
Hybrid
Finance & BankingCorporate Finance & FP&A

About the job

Requirements
  • At least 5 years of service delivery and management experience in a finance controlling environment.
  • Ability to manage change during the transition to the future Core model.
  • Ability to combine global-picture understanding with operational execution follow-up and management.
  • Advanced knowledge of risk and internal controls.
  • Demonstrated results building partnerships across multiple levels of the business.
  • Ability to influence and shape business decisions.
  • Ability to lead and manage a team of at least 8 members and stakeholders through influence, including facilitator skills.
  • Ability to track and manage a high volume of projects at a detailed level.
  • Ability to develop rapport and credibility with key stakeholders.
  • Ability to work effectively across international work streams.
  • Demonstrated organizational savvy and self-awareness.
  • Ability to adapt and work in a complex matrix environment.
  • Demonstrated experience modeling ethical behavior in challenging situations.
  • Excellent written and oral communication skills in English.
  • Strong analytical capabilities, attention to detail, and strategic thinking.
  • Proven experience working across multiple internal stakeholders.
  • Technology savvy, business orientation, and agile learning abilities.
  • Capability to work in multiple systems and tools.
  • Solid grasp of Sanofi technology platforms, processes, and controls, including SAP and TM1.
  • Bachelor’s degree in accounting or finance.
  • Please read Sanofi’s Code of Conduct before applying.
Responsibilities
  • Ensure efficient, high-quality, and compliant delivery of monthly closing, analysis, reporting, and forecasting services for headcount and personnel costs within the EMEA scope.
  • Ensure the end-to-end personnel cost service is efficient, cost-effective, high quality, and agile, meeting internal customer satisfaction and strategic KPI targets.
  • Create a culture of cooperation, collaboration, and teamwork across Controlling Operations, with a smooth interface and communication to relevant business stakeholders.
  • Define, propose, understand, and apply best practices from Controlling Operations or external best-in-class service organizations.
  • Ensure compliance and internal control/SOX standards are met; perform necessary controls and model compliance with Group ethical and compliance rules.
  • Support global transformation projects for Personnel Cost Controlling operations, aligning with the Global Core model, including TM1, ERP, and Insights Factory, and related process improvements.
  • Collaborate with Global Process Owners and the Global Head of Personnel Cost Controlling to support the design and implementation of key projects in operations.
  • Drive continuous improvement in the Personnel Cost Controlling team’s ways of working.
  • Ensure proper implementation according to the Core model and RACI of the Controlling Operations Hub organization.
  • Manage and arbitrate team workload planning and priorities, including oversight of Senior Financial Analysts responsible for personnel cost operational activities.
  • Supervise and monitor team members’ individual performance, including development plans, training plans, objectives, and career development.
  • Support Controlling Operations Service management teams, other Hub Service Delivery teams, and relevant stakeholders, and represent the Personnel Cost Controlling service delivery team.
  • Attend and contribute to functional and coordination meetings related to personnel cost topics.
  • Monitor Hub service delivery to ensure closing and reporting are performed within the Group calendar.
  • Perform other ad hoc projects and work within the Hub team.
  • Prepare monthly personnel cost closing activities for all business lines.
  • Validate and reconcile headcount.
  • Analyze personnel cost variances and prepare commentary.
  • Forecast and budget personnel costs.
  • Perform reporting and compliance activities.
  • Provide master data management support.
  • Perform global function controlling.
  • Manage multiple stakeholders to ensure internal and external factors affecting personnel costs are understood, communicated, and applied in financial forecasts and budgets.
  • Develop partnerships with other Budapest Service Delivery Lines to drive results and control forecasts and budgets.
Desired Qualifications
  • Ability to communicate in French.
  • MBA and/or CPA.
  • Pharmaceutical and public controlling/accounting experience.
  • Proven experience managing end-to-end processes related to headcount and personnel costs.
  • Experience with TM1 and SAP.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...